Supplementary Figure 4 from Expression of AR-V7 and ARv<sup>567es</sup> in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY

Confirmation of ARv567es amplicon by Sanger Sequencing A) Agarose gel electrophoresis showing the PCR-amplified ARv567es amplicon using ddPCR primers. Lane 1 DNA ladder from New England Biolabs, Inc; Lane 2 HEK293 cells transfected with Empty Vector (Negative control); Lane 3 HEK293 cells transfected with ARv567es-variant plasmid (Positive control); Lane 4 HEK293 cells transfected with ARv567es-variant plasmid, but with no reverse transcriptase (Negative control); Lanes 5-6 is CTC-derived DNA from patients #7 and #4 respectively. The red arrow depicts the expected size of ARv567es amplicon. B) Representative DNA chromatogram following Sanger Sequencing with the reverse and forward primers for the ARv567es amplicon (Size = 95 bps). Data shown for patient #7 amplicon.